Abiopharma

🔍 Ashe Gena L (Executive)

Company: Skyward Specialty Insurance Group, Inc. (SKWD)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 1,797 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,310.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 100 shares of Common Stock at $46.35 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,210.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 140 shares of Common Stock at $46.35 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,070.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 500 shares of Common Stock at $46.35 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,570.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,797 shares of 2025 RSU Award (Derivative)
  Date: 2026-05-11 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") settles for one share of the Issuer's Common Stock.
• F2: Sales to cover taxes and fees incurred in connection with the vesting and settlement of the Reporting Person's RSUs reported on this Form 4.
• F3: On May 7, 2025, the Reporting Person was granted an RSU Award in the amount of 1,797 RSUs. Subject to the terms of the RSU Agreement, this award fully vested on May 7, 2026.
• F4: The Reporting Person elected to sell shares to cover the associated tax liability incurred due to the vesting and settlement of the RSUs reported on this Form 4.The Issuer delayed the settlement, pursuant to the terms of the RSU Award Agreement, so that the sales to cover the tax liability occurred during an open trading window.